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هل حيمي مرض فقر الدم املنجلي من اإلصابة بداء السكري؟
دراسة مقطعية
علي عبدالنبي حممد، فتحية القر�ضي، ديفيد ويتفورد
abstract: Objectives: The co-existence of diabetes mellitus (DM) and sickle cell disease (SCD) is rare. This study 
aimed to explore whether SCD patients have the same DM prevalence as the general population in a country with a 
high prevalence of DM. Methods: This cross-sectional study included all SCD adult patients admitted to Salmaniya 
Medical Complex, Bahrain, between 2003 and 2010 (n = 2,204). A random sample (n = 520) was taken to establish 
the prevalence of DM. Laboratory records were examined to determine the presence of DM. Results: There were 
376 SCD patients with complete records; of these, 24 (6.4%) had DM. The age- and sex-standardised prevalence 
of DM was 8.3%. Conclusion: While the prevalence of DM in SCD patients in Bahrain was high, it was lower than 
expected in this population. SCD may have a protective effect towards DM development. However, the impact of 
these two conditions on vascular diseases suggest a need for screening and aggressive treatment in this population.
Keywords: Diabetes Mellitus; Sickle Cell Disease; Prevalence; Epidemiology; Comorbidity; Vascular Diseases; 
Bahrain.
امللخ�ص: الهدف: من النادر ح�ضول مر�س فقر الدم املنجلي وداء ال�ضكري يف نف�س املري�س معا. هذه الدرا�ضة تبحث يف ن�ضبة انت�ضار داء 
ال�ضكري يف املر�ضى امل�ضابني بفقر الدم املنجلي يف بلد ينت�رض فيه مر�س ال�ضكري بن�ضبة عالية. الطريقة: ا�ضتملت هذه الدرا�ضة املقطعية 
على كل مر�ضى فقر الدم املنجلي البالغني الذين اأدخلوا اإىل م�ضت�ضفى ال�ضلمانية الطبي يف البحرين، من �ضنة 2003 اإىل �ضنة 2010 )2,204 
مري�ضا(. مت اأخذ عينة ع�ضوائية من 520 مري�ضا لدرا�ضة معدل انت�ضار مر�س ال�ضكري بينهم. متت درا�ضة النتائج املختربية لفح�س ال�ضكري 
لتحديد وجود املر�س. النتائج: مت إدراج 376 مري�ضا بفقر الدم املنجلي وكانت �ضجلتهم الطبية كاملة يف الدرا�ضة. وجد أن24 مريضا منهم 
%6.4 م�ضابون بال�ضكري. كان معدل انت�ضار داء ال�ضكري يف مر�ضى فقر الدم املنجلي بعد �ضبط النتائج بناء على العمر واجلن�س هو8.3%. 
اخلال�صة: يف حني اأّن معدل انت�ضار داء ال�ضكري يف املر�ضى امل�ضابني بفقر الدم املنجلي يف البحرين و�ضل إيل ن�ضبة عالية، اإاّل اأنها اأقل 
من املتوقع يف هذه الفئة ال�ضكانية. هذا ي�ضري اإىل احتمالية وجود تاأثري وقائي ملر�س فقر الدم املنجلي نحو االإ�ضابة بداء ال�ضكري. ولكن 
مع ذلك، فاإّن تاأثري هذين املر�ضني ال�ضلبي على االإ�ضابة باأمرا�س االأوعية الدموية ي�ضري اإىل اأهمية الفح�س املربمج والعلج الوقائي لهذه 
العوامل يف هذه الفئة من املر�ضى.
ِرّي؛ مر�س فقر الدم املنجلي؛ مدى االْنِت�ضار؛ الَوباِئيَّات؛ املرا�ضة امل�ضرتكة؛ اأمرا�س االأوعية الدموية؛ البحرين. كَّ مفتاح الكلمات: ال�ضُّ
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Sickle cell disease (SCD) is one of the most common inherited haemoglobinopathies.1 The leading cause of death among patients 
with SCD has changed from infections to chronic 
cardiopulmonary complications.2 Diabetes mellitus 
(DM) is a major risk factor for cardiovascular diseases, 
accounting for an increased risk of myocardial 
infarctions or strokes.3 In addition, DM patients are 
predisposed to complications that are also associated 
with SCD, including infections, renal failure and 
retinopathy. Fortunately, research has indicated that 
the co-existence of type 1 and type 2 DM with SCD 
is rare; several studies have found no cases of DM at 
all among SCD patients.4,5 A large multi-centre study, 
carried out in 31 centres in the USA, Canada and the 
UK, revealed that only 2% of blood-transfused SCD 
patients also had DM.6 
Bahrain has a population of approximately 1.2 
million, although around 50% are expatriates.7 The 
country has a high prevalence of both DM and SCD, 
ranking fifth in the world for DM at 15.8%.8 The 
prevalence of SCD in Bahrain was 2.1% in 1987,9 
but this prevalence had decreased by 1.3% in 2008.10 
Both diseases present considerable challenges to the 
national healthcare system.11,12 The co-existence of 
these two conditions in a population where both are 
highly prevalent has not been previously studied. 
Therefore, this preliminary study aimed to explore 
whether patients with SCD have the same prevalence 
of DM as the general population in Bahrain.
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Methods
The medical records of all patients with SCD aged 18 
years and over who were admitted to the Salmaniya 
Medical Complex in Manama, Bahrain, between 
January 2003 and December 2010 were included in 
this study (n = 2,204). The Salmaniya Medical Complex 
is the single government sickle cell service available in 
the country. The majority of patients attending this 
clinic are of Arab descent. 
Based on the population size, a random sample of 
327 patients was calculated as the minimum sample 
required to establish the prevalence of DM with a 5% 
margin of error. In order to allow for missing medical 
records and data, a computer-generated random 
sample of 520 subjects was taken. However, 26 patients 
(5%) were subsequently found not to have SCD 
based on their haemoglobin electrophoresis results. 
These patients were therefore removed from the 
sample (n = 494).
Data from the patients’ medical records were 
collected, including age, gender, fasting blood sugar 
levels, random blood sugar levels, glucose tolerance test 
results and haemoglobin electrophoresis (haemoglobin 
S and fetal haemoglobin percentages). Laboratory data 
from other governmental health centres and hospitals in 
Bahrain were accessed through a centralised repository. 
Patients were categorised into the following four 
groups according to the World Health Organization’s 
(WHO) diagnostic criteria for DM: diagnosed or 
undiagnosed DM; impaired fasting glucose and/
or impaired glucose tolerance (also known as pre-
diabetes); no DM, or unknown DM status due to 
insufficient or missing blood results.13
Among the patients included in the study, DM 
was ruled out by two normal readings of fasting 
or random blood glucose levels on two separate 
days. Haemoglobin A1c levels were not used to 
either establish or rule out a diagnosis of DM, as 
these measurements are unreliable in patients with 
haemoglobinopathies such as SCD.14 A total of 118 
patients (22.7%) had insufficient data in their medical 
records to establish their diabetic status. These patients 
were therefore excluded from the analysis, resulting in 
a final sample of 376.
The study sample was statistically compared to 
data from the 2010 census of the Bahraini population 
in order to establish the age- and sex-standardised 
prevalence of DM in the sample.7 Data were analysed 
using JMP-IN®, Version 9 (SAS Institute Inc., Cary, 
North Carolina, USA) with descriptive statistics and 
non-parametric tests of association.
Ethical approval for this study was granted by 
the Research Ethics Committee of the Royal College 
of Surgeons in Ireland (RCSI) Medical University of 
Bahrain, as well as the Research Technical Support 
Team of the Bahraini Ministry of Health and the 
Research Committee of Salmaniya Medical Complex.
Results 
There were 376 SCD patients with complete records. 
The mean age was 33.5 ± 11.2 years (range: 18–79 
years). There were 196 male patients (52.1%) among 
the cohort, which was consistent with the gender 
ratio of the general Bahraini population (1.07 versus 
1.01, respectively; P = 0.47).7 However, the sample 
had a lower proportion of individuals aged >55 years 
in comparison to the general Bahraini population 
(4.4% versus 9.8%, respectively; P <0.001). The mean 
number of hospital admissions was 14.5 ± 24.4 with a 
range of 1–195 admissions. 
Of the final sample, 24 SCD patients (6.4%) were 
determined to have either type 1 or type 2 DM. A total 
of 11 patients had previously been diagnosed with DM 
and their diagnosis was confirmed by recent glucose 
measurements. A further 13 patients had sufficiently 
raised blood glucose levels to establish a diagnosis 
of DM according to WHO criteria. In addition, 32 
patients (8.5%) were found to have impaired fasting 
glucose or impaired glucose tolerance. 
As expected, the prevalence of DM rose with age 
(χ2 = 42.9; degrees of freedom [df ] = 2; P <0.0001). The 
prevalence of DM in patients aged ≥40 years was 16.4% 
(17 out of 103 patients). The age- and sex-standardised 
prevalence of DM was 8.3% while impaired glucose 
tolerance/impaired fasting glucose was 11.0%. No 
association was found between DM and gender (χ2 = 
1.5; df = 2; P = 0.47) or number of hospital admissions 
(χ2 = 2.2; df = 2; P = 0.34).
Discussion 
Previous studies have found low or non-existent rates 
of DM in patients with SCD.4‒6 This has led to the 
hypothesis that SCD may inhibit the inheritance or the 
development of DM through a genetic mechanism.15 
Alternative explanations include the lowered life 
expectancy of SCD patients, which reduces the 
likelihood of overt DM developing over time,15 or the 
increased frequency of illnesses among SCD patients 
population, which leads to an underweight population 
with a lower predisposition to DM.16
A high age- and sex-standardised prevalence of 
DM was found among the studied Bahraini patients 
with SCD (8.3%). However, this was still lower than 
the expected prevalence (15.4%) among the general 
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population of Bahrain [Figure 1].8,17 Despite this, the 
prevalence of DM among the studied cohort was not as 
uncommon as other studies based outside of Bahrain 
have indicated.4–6 The prevalence of DM in the general 
Bahraini population aged ≥40 years is approximately 
30%,17 as can be seen in Figure 1, this is almost double 
the rate of DM that was observed among SCD patients 
of the same age category in the current study. Lower 
life expectancy was excluded as an explanation for 
the lower prevalence of DM in these SCD patients 
by statistical adjustments of age. However, decreased 
rates of obesity in the SCD population may be 
responsible for the low observed prevalence of DM. 
Subsequent matched case-control or cohort studies 
are recommended in order to establish an age-, sex- 
and body mass index-adjusted prevalence for DM in 
patients with SCD in Bahrain and the Gulf.
Although the prevalence of DM among the 
studied cohort was lower than expected, the rate of 
DM found among the studied SCD patients is still 
high enough to raise concerns about the potential 
impact of these two co-existing conditions on the 
development of cardiovascular disease. To the best 
of the authors’ knowledge, no published studies have 
yet observed that the occurrence of SCD alongside 
DM leads to poorer outcomes; however, the co-
existence of vascular risk factors (e.g. hypertension or 
smoking) could theoretically lead to further increased 
vascular risk. As a result, there may be a need for both 
structured screening programmes and the aggressive 
treatment of vascular risk factors in this population. 
Furthermore, additional research is recommended to 
identify the potential factors of SCD which may have a 
protective effect against the development of DM. 
This study was undertaken as a preliminary study 
to determine whether the lower prevalence of DM 
in patients with SCD established in several previous 
studies would be reflected in this highly prevalent 
Bahraini population.4–6 The results of this rapid and cost-
effective study shed light on the potential protective 
effect of SCD over DM. Nonetheless, the results should 
be interpreted in light of several limitations. While 
the selection of a nationally-representative sample 
was assured due to the existence of a single centre in 
Bahrain serving all patients with SCD, the study was 
retrospective in nature and therefore limited to patients 
with hospital admissions—however, it is probable that 
most adults with SCD would have been admitted at 
least once during the seven-year study period. As a 
result, a portion of the population with milder SCD 
may have been excluded, leading to a selection bias. 
This bias may have led to an underestimation of the 
DM prevalence.
In addition, this study was also dependent on 
available laboratory glucose results; any recently 
developed symptoms of DM may have been missed, 
thereby potentially resulting in an underestimation of 
the prevalence. Furthermore, since it was not possible 
to obtain sufficient data to establish patients’ body 
mass indexes, a link between lower rates of obesity and 
a lower prevalence of DM among the SCD could not 
be excluded. Data regarding any medications were also 
not obtained and this may have led to an additional 
underestimation of the DM prevalence. Moreover, 
other confounding factors, including ethnicity, were 
not accounted for.
It would be of interest to establish whether other 
cardiovascular risk factors, such as hypertension and 
hyperlipidaemia, are less prevalent in patients with 
SCD. In spite of these limitations, this is the first study 
of its kind in a population with a high prevalence of 
both DM and SCD and adds to the existing literature 
that suggests a lower prevalence of DM among patients 
with SCD. 
Conclusion
While the prevalence of DM among the studied SCD 
patients in Bahrain was high (8.3%), it was lower than 
expected among this population. Lower rates of obesity 
in this population may be responsible for the low 
observed prevalence of DM. Alternatively, there may be 
a genetic or epigenetic protective effect of SCD towards 
the development of DM. Nevertheless, the impact of 
these two conditions on the development of vascular 
disease suggests a need for screening and the aggressive 
treatment of vascular risk factors in this population.
 
Figure 1: Comparison of the age- and sex-adjusted 
prevalence of diabetes found among the studied sickle 
cell disease cohort in Bahrain (N = 376) with the prevalence 
of diabetes among the general population in Bahrain. 
*Data sourced from International Diabetes Federation. IDF 
Diabetes Atlas: Fourth edition8 and al-Mahroos, McKeigue 
PM. High prevalence of diabetes in Bahrainis: Associations with 
ethnicity and raised plasma cholesterol.17
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